Advisors Asset Management’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.18M Buy
6,431
+219
+4% +$40.4K 0.02% 750
2025
Q4
$1.09M Buy
6,212
+132
+2% +$21.6K 0.02% 769
2025
Q3
$852K Buy
6,080
+367
+6% +$49.6K 0.01% 839
2025
Q2
$717K Sell
5,713
-671
-11% -$83.6K 0.01% 872
2025
Q1
$874K Sell
6,384
-239
-4% -$34.2K 0.02% 789
2024
Q4
$1.01M Sell
6,623
-73
-1% -$12.3K 0.02% 735
2024
Q3
$1.3M Buy
6,696
+147
+2% +$30.8K 0.02% 676
2024
Q2
$1.52M Sell
6,549
-892
-12% -$194K 0.03% 617
2024
Q1
$1.6M Buy
7,441
+451
+6% +$106K 0.03% 617
2023
Q4
$1.81M Buy
6,990
+1,120
+19% +$275K 0.04% 557
2023
Q3
$1.51M Sell
5,870
-16
-0.3% -$4.28K 0.03% 585
2023
Q2
$1.68M Buy
5,886
+572
+11% +$170K 0.03% 573
2023
Q1
$1.48M Sell
5,314
-158
-3% -$43.7K 0.03% 608
2022
Q4
$1.52M Sell
5,472
-234
-4% -$66.1K 0.03% 591
2022
Q3
$1.52M Buy
5,706
+335
+6% +$71.1K 0.03% 572
2022
Q2
$1.09M Buy
5,371
+998
+23% +$204K 0.02% 729
2022
Q1
$921K Sell
4,373
-911
-17% -$198K 0.01% 834
2021
Q4
$1.27M Buy
5,284
+236
+5% +$60.7K 0.02% 765
2021
Q3
$1.43M Buy
5,048
+55
+1% +$18K 0.02% 706
2021
Q2
$1.73M Buy
4,993
+507
+11% +$154K 0.03% 636
2021
Q1
$1.25M Buy
4,486
+1,360
+44% +$367K 0.02% 753
2020
Q4
$765K Buy
3,126
+1,462
+88% +$377K 0.01% 847
2020
Q3
$472K Buy
1,664
+76
+5% +$21.2K 0.01% 936
2020
Q2
$425K Sell
1,588
-366
-19% -$110K 0.01% 945
2020
Q1
$618K Sell
1,954
-488
-20% -$148K 0.01% 756
2019
Q4
$725K Sell
2,442
-570
-19% -$158K 0.01% 860
2019
Q3
$701K Sell
3,012
-1,496
-33% -$348K 0.01% 876
2019
Q2
$1.05M Sell
4,508
-585
-11% -$135K 0.02% 762
2019
Q1
$1.2M Sell
5,093
-1,287
-20% -$405K 0.02% 751
2018
Q4
$1.92M Sell
6,380
-7,887
-55% -$2.52M 0.04% 516
2018
Q3
$5.04M Sell
14,267
-829
-5% -$285K 0.08% 294
2018
Q2
$4.38M Buy
15,096
+1,115
+8% +$313K 0.07% 336
2018
Q1
$4.03M Buy
13,981
+179
+1% +$55.6K 0.07% 385
2017
Q4
$4.4M Buy
13,802
+465
+3% +$149K 0.07% 366
2017
Q3
$4.18M Buy
13,337
+5,160
+63% +$1.53M 0.07% 392
2017
Q2
$2.22M Buy
8,177
+19
+0.2% +$5.02K 0.04% 591
2017
Q1
$2.23M Sell
8,158
-5,579
-41% -$1.58M 0.04% 592
2016
Q4
$3.9M Sell
13,737
-5,403
-28% -$1.6M 0.06% 414
2016
Q3
$5.99M Sell
19,140
-3,985
-17% -$1.18M 0.1% 298
2016
Q2
$5.59M Sell
23,125
-1,494
-6% -$394K 0.09% 329
2016
Q1
$6.41M Sell
24,619
-3,306
-12% -$873K 0.11% 273
2015
Q4
$8.55M Buy
27,925
+1,483
+6% +$426K 0.14% 216
2015
Q3
$7.72M Buy
26,442
+6,118
+30% +$2.02M 0.12% 234
2015
Q2
$8.21M Buy
20,324
+2,858
+16% +$1.15M 0.11% 246
2015
Q1
$7.38M Buy
17,466
+1,590
+10% +$627K 0.1% 263
2014
Q4
$5.39M Buy
15,876
+743
+5% +$240K 0.07% 332
2014
Q3
$5.01M Buy
15,133
+529
+4% +$174K 0.07% 338
2014
Q2
$4.61M Sell
14,604
-1,239
-8% -$373K 0.06% 354
2014
Q1
$4.85M Sell
15,843
-905
-5% -$287K 0.07% 320
2013
Q4
$4.68M Sell
16,748
-1,199
-7% -$310K 0.08% 327
2013
Q3
$4.32M Sell
17,947
-1,900
-10% -$425K 0.08% 324
2013
Q2
$4.27M Buy
+19,847
New +$4.24M 0.08% 304

Other funds holding BIIB

Advisors Asset Management's BIIB Position: Q1 2026 in Review

Advisors Asset Management increased its Biogen (BIIB) stake by 3.5% in Q1 2026, buying an estimated $40.4K and bringing the position to 6,431 shares worth $1.18M. The position accounts for 0.02% of the portfolio, ranked #750.

Advisors Asset Management first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $8.55M in Q4 2015. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Advisors Asset Management held 6,431 shares of Biogen worth $1.18M as of Q1 2026.
  • Advisors Asset Management bought 219 Biogen shares in Q1 2026, an estimated $40.4K.
  • Biogen made up 0.02% of Advisors Asset Management's portfolio in Q1 2026, its #750 holding.
  • Advisors Asset Management first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
  • Advisors Asset Management's Biogen position peaked at $8.55M in Q4 2015.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Advisors Asset Management's 13F filing for Q1 2026, filed 15 May 2026.